## LATHAM&WATKINS LLP

October 9, 2012

## **VIA EDGAR**

James Peklenk Staff Accountant Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

File No. 0-50679

Corcept Therapeutics, Inc. (the "Company") Re: Form 10-K for the Fiscal Year Ended December 31, 2011 Filed March 13, 2012 Form 10-Q for the Quarterly Period Ended June 30, 2012 Filed August 9, 2012

Dear Mr. Peklenk:

Reference is made to the letter dated September 25, 2012 from the Staff relating to the above-referenced filings. As discussed, the Company has requested additional time to respond to the comments from the Staff. The Company expects to respond to the Staff's comments on or before October 24, 2012.

Please contact the undersigned at (650) 463-2677 if you have any questions regarding this request.

Very truly yours,

/s/ Kathleen M. Wells

Kathleen M. Wells of LATHAM & WATKINS LLP

G. Charles Robb, Chief Financial Officer

140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600

www.lw.com

FIRM / AFFILIATE OFFICES Abu Dhabi Moscow Munich Barcelona Beijing New Jersey Boston New York Brussels Orange County Chicago Paris Doha Dubai Riyadh Rome Frankfurt San Diego Hamburg San Francisco Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles

Tokyo

Washington, D.C.

Madrid Milan